- Home
- YSG vs XOMA Comparison
YSG vs XOMA Comparison
Compare YSG & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- XOMA
- Stock Information
- Founded
- YSG 2016
- XOMA 1981
- Country
- YSG China
- XOMA United States
- Employees
- YSG N/A
- XOMA N/A
- Industry
- YSG Package Goods/Cosmetics
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- YSG Consumer Discretionary
- XOMA Health Care
- Exchange
- YSG Nasdaq
- XOMA Nasdaq
- Market Cap
- YSG 396.8M
- XOMA 355.6M
- IPO Year
- YSG 2020
- XOMA N/A
- Fundamental
- Price
- YSG $3.89
- XOMA $30.71
- Analyst Decision
- YSG
- XOMA Strong Buy
- Analyst Count
- YSG 0
- XOMA 2
- Target Price
- YSG N/A
- XOMA $78.50
- AVG Volume (30 Days)
- YSG 275.6K
- XOMA 19.5K
- Earning Date
- YSG 11-19-2024
- XOMA 11-07-2024
- Dividend Yield
- YSG N/A
- XOMA N/A
- EPS Growth
- YSG N/A
- XOMA N/A
- EPS
- YSG N/A
- XOMA N/A
- Revenue
- YSG $462,190,479.00
- XOMA $21,606,000.00
- Revenue This Year
- YSG $2.29
- XOMA $456.45
- Revenue Next Year
- YSG $5.70
- XOMA $29.84
- P/E Ratio
- YSG N/A
- XOMA N/A
- Revenue Growth
- YSG N/A
- XOMA 389.82
- 52 Week Low
- YSG $1.99
- XOMA $14.27
- 52 Week High
- YSG $4.89
- XOMA $33.78
- Technical
- Relative Strength Index (RSI)
- YSG 60.56
- XOMA 53.45
- Support Level
- YSG $3.77
- XOMA $26.74
- Resistance Level
- YSG $4.00
- XOMA $33.78
- Average True Range (ATR)
- YSG 0.16
- XOMA 1.56
- MACD
- YSG 0.02
- XOMA 0.10
- Stochastic Oscillator
- YSG 79.66
- XOMA 49.15
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.